Compound screening using cardiomyocytes

Details Compound screening using cardiomyocytes Compound screening using cardiomyocytes

2008-09-22

2010-12-14

Ton, Thaian N (Department: 1632)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S325000, C435S363000, C435S366000, C435S377000

Reexamination Certificate

active

07851167

ABSTRACT:
This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease.

REFERENCES:
patent: 5543318 (1996-08-01), Smith et al.
patent: 5733727 (1998-03-01), Field
patent: 5843780 (1998-12-01), Thomson
patent: 5928943 (1999-07-01), Franz et al.
patent: 6015671 (2000-01-01), Field
patent: 6099832 (2000-08-01), Mickle et al.
patent: 6110459 (2000-08-01), Mickle et al.
patent: 6245566 (2001-06-01), Gearhart et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6387369 (2002-05-01), Pittenger et al.
patent: 6399300 (2002-06-01), Field
patent: 6534052 (2003-03-01), Xiao et al.
patent: 7368420 (2008-05-01), Walsh
patent: 7425448 (2008-09-01), Xu
patent: 7452718 (2008-11-01), Gold et al.
patent: 2002/0061837 (2002-05-01), Lough, Jr. et al.
patent: 2002/0142457 (2002-10-01), Umezawa et al.
patent: 2002/0146678 (2002-10-01), Benvenisty
patent: 2004/0005701 (2004-01-01), Xu et al.
patent: 2004/0022367 (2004-02-01), Talalai
patent: 2005/0037489 (2005-02-01), Gepstein et al.
patent: 2005/0054092 (2005-03-01), Xu et al.
patent: 2005/0164382 (2005-07-01), Xu
patent: 2005/0214938 (2005-09-01), Gold et al.
patent: 2005/0227353 (2005-10-01), Mummery
patent: 2005/0266554 (2005-12-01), D'Amour et al.
patent: 2009/0047739 (2009-02-01), Gold et al.
patent: 729377 (2001-02-01), None
patent: WO 92/13066 (1992-08-01), None
patent: WO 95/14079 (1995-05-01), None
patent: WO 99/49015 (1999-09-01), None
patent: WO 00/06701 (2000-02-01), None
patent: WO 00/70021 (2000-11-01), None
patent: WO 00/78119 (2000-12-01), None
patent: WO 01/22978 (2001-04-01), None
patent: WO 01/48151 (2001-07-01), None
patent: WO 01/51616 (2001-07-01), None
patent: WO 01/53465 (2001-07-01), None
patent: WO 01/68814 (2001-09-01), None
patent: WO 02/09650 (2002-02-01), None
patent: WO 02/13760 (2002-02-01), None
patent: WO 02/19893 (2002-03-01), None
patent: WO 02/30206 (2002-04-01), None
patent: WO 02/083864 (2002-10-01), None
patent: WO 03/006950 (2003-01-01), None
patent: WO 2004/081205 (2004-09-01), None
Piao et al. Biotechnol. Appl. Biochem., 37:27-30, 2003.
Goldman et al. Exp. Cell Res., 228: 237-245, 1996.
Tweedie et al. J. Mol. Cell Cardiol., 29: 1457-1467, 1997.
“Isoprenaline” from Wikipedia, accessed online at www.en.wikipedia.com on Mar. 25, 2009.
“Alpha-1 adrenergic receptor” from Wikipedia, accessed online at www.en.wikipedia.com on Mar. 26, 2009.
Cerbai et al. J. of Cardiovascular Pharmacology, 36(5): 584-591, Nov. 2000.
Corsini et al. J. of Cardiovascular Pharmacology, 28: 687-694, 1996.
Feng et al. Circ. Res., 80: 572-579, 1997.
Alsan, B. & Schultheiss, T., “Regulation of avian cardiogenesis by Fgf8 signaling,”Development129:1935-43 (2002).
Andráe, B. et al., “BMP-2 induces ectopic expression of cardiac lineage markers and interferes with somite formation in chicken embryos,”Mech. Dev. 70:119-31 (1998).
Antin, P. et al., “Regulation of avian precardiac mesoderm development by insulin and insulin-like growth factors,”J. Cell. Physiol. 168:42-50 (1996).
Arai, A. et al., “Murine cardiac progenitor cells require visceral embryonic endoderm and primitive streak for terminal differentiation,” Dev. Dynamics 210:344-53 (1997).
Barron, M. et al., “Requirement for BMP and FGF signaling during cardiogenic induction in non-precardiac mesoderm is specific, transient, and cooperative,”Dev. Dynamics218:383-93 (2000).
Bauwens, C. et al., “Development of a perfusion fed bioreactor for embryonic stem cell-derived cardiomyocyte generation: oxygen-mediated enhancement of cardiomyocyte output,”Biotechnol. Bioeng. 90(4):452-61 (2005).
Behfar, A. et al., “Stem cell differentiation requires a paracrine pathway in the heart,”FASEB J. 16:1558-66 (2002).
Caspi, O. & Gepstein, L., “Potential applications of human embryonic stem cell-derived cardiomyocytes,”Ann. N.Y. Acad. Sci. 1015:285-298 (2004).
Charron, F. and Nemer, M., “GATA transcription factors and cardiac development,”Sem. Cell Dev. Biol. 10:85-91 (1999).
Claycomb, W. et al., “HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte,”Proc. Natl. Acad. Sci. USA95:2979-84 (1998).
Czyz, J. et al., “Potential of embryonic and adult stem cells in vitro,”Biol. Chem. 384:1391-409 (2003).
Dang, S. et al., “Controlled, scalable embryonic stem cell differentiation culture,”Stem Cells22:275-82 (2004).
Doevendans, P. et al., “Differentiation of cardiomyocytes in floating embryoid bodies is comparable to fetal cardiomyocytes,”J. Mol. Cell Cardiol. 32:839-51 (2000).
Dubus, I. et al., “Contractile protein gene expression in serum-free cultured adult rat cardiac myocytes,”Pflügers Arch. 423:455-61 (1993).
Fukuda, K., “Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering,”Artificial Organs25(3):187-93 (2001).
Gepstein, L., “Derivation and potential applications of human embryonic stem cells,”Circ. Res. 91(10):866-76 (2002).
Gerecht-Nir, S. et al., “Vascular gene expression and phenotypic correlation during differentiation of human embryonic stem cells,”Dev. Dyn. 232:487-97 (2005).
Goh, G. et al., “Molecular and phenotypic analyses of human embryonic stem cell-derived cardiomyocytes,”Thromb. Haemost. 94:728-37 (2005).
Grépin, C. et al., “Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor,”Development124:2387-95 (1997).
Gryshchenko, O. et al., “Outwards currents in embryonic stem cell-derived cardiomyocytes,”Pflügers Arch—Eur. J. Physiol. 439:798-807 (2000).
Heng, B. et al., “Strategies for directing the differentiaion of stem cells into the cardiomyogenic lineage in vitro,”Cardiovascular Res. 62:34-42 (2004).
Itskovitz-Eldor, J. et al., “Differentiation of human embronic stem cells into embryoid bodies comprising the three embryonic germ layers,”Molec. Med. 6(2):88-95 (2000).
Johansson, B. & Wiles, M., “Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development,”Molec. Cell. Biol. 15(1):141-51 (1995).
Kawai, T. et al., “Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2,”Circ. J. 68:691-702 (2004).
Kehat, I. et al., “Electromechanical integration of cardiomyocytes derived from human embryonic stem cells,”Nature Biotechnol. 22(10):1282-89 (2004).
Kehat, I. et al., “Human embryonic stem cells can diffrentiate into myocytes with structural and functional properties of cardiomyocytes,”J. Clin. Invest. 108(3):407-14 (2001).
Kehat, I. et al., “Long term high-resolution, electrophysiological assessment of human embryonic stem cell derived cardiomyocytes: A novel in vitro model for the human heart,”Circulation102(18 Suppl. II):II-4 Abstract 6 (2000).
Kessler, P. & Byrne, B., “Myoblast cell grafting into heart muscle: Cellular biology and potential applications,”Annu. Rev. Physiol. 61:219-42 (1999).
Khamsi, R. “Geneticists hail variety show, map of DNA differences will help experts tailor drugs,”Nature, online, 2 pages (Oct. 26, 2005).
Khamsi, R. “Market Watch,”Nature437:1231 (2005).
Klug, M. et al., “Gen

Affiliated with

Also associated with

Rating

Compound screening using cardiomyocytes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compound screening using cardiomyocytes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compound screening using cardiomyocytes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4214492